besilesomab
Various (V09)Various (V09) compound in Telix Innovations's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
pharma · Metastatic Prostate Cancer · Prostate Cancer · TLX
Telix Innovations
Telix Innovations drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Rue de Hermée 255, Herstal, Région wallonne 4040, BE HQ
2015 Founded
14 Employees
Public company Type
TLX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Rue de Hermée 255, Herstal, Région wallonne 4040, BE
- Founded
- 2015
- Employees
- 14
- Programs
- 27
- Drugs
- 11
- Patents
- 3
Telix Innovations pipeline
Portfolio lens on 11 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Telix Innovations drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Telix Innovations in public FDA and regional records.
-
fluciclovine (18f)
Various (V09)Various (V09) compound in Telix Innovations's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
lutetium (177lu) chloride
Various (V10)Various (V10) compound in Telix Innovations's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
olaratumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Platelet-derived growth factor receptor alpha.
- Target
- Platelet-derived growth factor receptor alpha
- Mechanism
- Platelet-derived growth factor receptor alpha antagonist
-
orlistat
Alimentary tract and metabolism (A08)US regulatory status: approved. Molecular target: Gastric triacylglycerol lipase.
- Target
- Gastric triacylglycerol lipase
- Mechanism
- Pancreatic lipase inhibitor
-
sodium zirconium cyclosilicate
Various (V03)US regulatory status: approved. Molecular target: Potassium.
- Target
- Potassium
- Mechanism
- Potassium chelating agent
-
Development asset linked to Telix Innovations in public FDA and regional records.